Prenetics Global LtdPRE

NasdaqHealthcarePharmaceutical Preparations
Price (close)
$22.93
Market cap
$386.9M
P/E
—
Revenue (FY)
$30.6M
Net income
-$46.3M
Dividend yield
—
1-year total return
86.3%
Net margin
-151.2%
Revenue growth
40.8%
Debt / equity
—

What Prenetics Global Ltd does.

We are a consumer health company advancing human health and longevity through science-backed products, global brand partnerships, and AI-driven operations. Our flagship brand, IM8—co-founded with David Beckham—generated $60.1 million in revenue in its first full fiscal year, achieved $120 million in ARR as of December 2025, and ships to more than 30 countries.

IM8 was developed in collaboration with our Scientific Advisory Board that includes experts from Cedars-Sinai and leading academic institutions. The brand was built to address a specific market gap: the supplement industry’s chronic deficit of products combining clinical-grade formulation with consumer-grade brand experience. David Beckham, as co-founding partner, was instrumental in shaping the brand’s vision and provides IM8 with organic global demand generation through his 85+ million Instagram following and cultural relevance across markets.

Our Company’s total revenue in Q4 2025 reached $36.6 million, a 457% year-over-year increase and 55% quarter-over-quarter increase. Q4 2025 gross margin improved to approximately 59%, up from approximately 37% from the same period in the prior year—a nearly 2,300 basis point improvement driven by the increasing dominance of IM8’s premium unit economics in the revenue mix. Based on current cohort performance and modeled retention trends, IM8 is projected to achieve LTV:CAC ratios above 3x across its product portfolio, including premium offerings such as the Beckham Stack.

Revenue and profit, by fiscal year.

Fiscal year201920202021202220232024
Revenue—$65.2M$12.5M$13.2M$21.7M$30.6M
Net income—-$1.9M-$174.0M-$190.5M-$62.7M-$46.3M
Free cash flow—-$5.7M$4.9M$9.6M-$14.1M-$29.9M

More on PRE.

Figures from Prenetics Global Ltd's filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.